This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: 93/1/300    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goodarzi, M. O. Articles by Azziz, R. Search for Related Content PubMed PubMed Citation Articles by Goodarzi, M. O. Articles by Azziz, R. Related Collections Female Endocrinology

Nonreplication of the Type 5 17β-Hydroxysteroid Dehydrogenase Gene Association with Polycystic Ovary Syndrome

Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine (M.O.G., M.R.J., H.J.A.), Department of Obstetrics and Gynecology (M.O.G., M.P., R.A.), and Medical Genetics Institute (M.O.G., Y-D.I.C.), Cedars-Sinai Medical Center, Los Angeles, California 90048; and Departments of Medicine (M.O.G., Y.-D.I.C., R.A.) and Obstetrics and Gynecology (R.A.), the David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California 90095

Address all correspondence and requests for reprints to: Ricardo Azziz, M.D., M.P.H., M.B.A., Department of Ob/Gyn and Center for Androgen Related Disorders, Cedars-Sinai Medical Center, 8635 West Third Street, Suite 160W, Los Angeles, California 90048. E-mail: azzizr{at}cshs.org.

Context: Increased androgen production is a primary feature of polycystic ovary syndrome (PCOS) and appears to be an inherited trait. The gene for the steroidogenic enzyme type 5 17β hydroxysteroid dehydrogenase (HSD17B5) was implicated as a candidate for the hyperandrogenemia of PCOS by a previous study that demonstrated an association of a single nucleotide polymorphism (SNP) in the promoter of this gene with PCOS.

Objective: The objective of the study was to replicate the previous report of association between the HSD17B5 gene and PCOS risk by genotyping the promoter SNP (as well as other SNPs in the region to provide improved coverage of the gene) in a large, well-characterized cohort suitable for replication study.

Design: Women with and without PCOS were genotyped for five SNPs in HSD17B5. SNPs and haplotypes were determined and tested for association with PCOS risk and phenotypic markers of PCOS.

Setting: Subjects were recruited from the reproductive endocrinology clinic at the University of Alabama at Birmingham; controls were recruited from the surrounding community. Genotyping took place at Cedars-Sinai Medical Center in Los Angeles.

Participants: Participants included 287 white women with PCOS and 187 white controls.

Main Measurements: HSD17B5 genotype, PCOS risk, and testosterone levels were measured.

Results: No SNP or haplotype was significantly associated with PCOS risk, testosterone, or any of the traits tested.

Conclusions: These data suggest that polymorphisms in the HSD17B5 gene are not associated with PCOS risk or elevated testosterone as previously reported.

This article has been cited by other articles:

				J. M Day, H. J Tutill, A. Purohit, and M. J Reed Design and validation of specific inhibitors of 17{beta}-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis Endocr. Relat. Cancer, September 1, 2008; 15(3): 665 - 692. [Abstract] [Full Text] [PDF]

				R. Azziz Polycystic Ovary Syndrome Is a Family Affair J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1579 - 1581. [Full Text] [PDF]